PA8623101A1 - Compuestos farmaceuticamente activos - Google Patents

Compuestos farmaceuticamente activos

Info

Publication number
PA8623101A1
PA8623101A1 PA20058623101A PA8623101A PA8623101A1 PA 8623101 A1 PA8623101 A1 PA 8623101A1 PA 20058623101 A PA20058623101 A PA 20058623101A PA 8623101 A PA8623101 A PA 8623101A PA 8623101 A1 PA8623101 A1 PA 8623101A1
Authority
PA
Panama
Prior art keywords
active compounds
pharmaceutically active
processes
mcr4
melanocortin
Prior art date
Application number
PA20058623101A
Other languages
English (en)
Inventor
David Hepworth
Andrew Antony Calabresse
David Sebastienfradet
Mark Lansdell
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34864830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8623101(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0412417A external-priority patent/GB0412417D0/en
Priority claimed from GB0425530A external-priority patent/GB0425530D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of PA8623101A1 publication Critical patent/PA8623101A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA CLASE DE AGONISTAS DE MELANOCORTINA CR4 DE FORMULA GENERAL (I) EN LA QUE R1, R2, R3, R4 y R5 SON COMO SE HAN DEFINIDO ANTERIORMENTE Y ESPECIALMENTE A COMPUESTOS AGONISTAS SELECTIVOS DE MCR4, A SU USO EN MEDICINA, A COMPOSICIONES QUE LOS CONTIENEN, A PROCESOS PARA SU PREPARACION Y A INTERMEDIOS USADOS EN TALES PROCESOS.
PA20058623101A 2004-02-04 2005-02-04 Compuestos farmaceuticamente activos PA8623101A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0402492.3A GB0402492D0 (en) 2004-02-04 2004-02-04 Pharmaceutically active compounds
GB0412417A GB0412417D0 (en) 2004-06-03 2004-06-03 Pharmaceutically active compounds
GB0425530A GB0425530D0 (en) 2004-11-19 2004-11-19 Pharmaceutically active compounds

Publications (1)

Publication Number Publication Date
PA8623101A1 true PA8623101A1 (es) 2006-05-16

Family

ID=34864830

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058623101A PA8623101A1 (es) 2004-02-04 2005-02-04 Compuestos farmaceuticamente activos

Country Status (25)

Country Link
EP (1) EP1716135B1 (es)
JP (1) JP4031814B2 (es)
KR (1) KR100830763B1 (es)
CN (1) CN1930146A (es)
AP (1) AP2006003699A0 (es)
AR (1) AR048232A1 (es)
AT (1) ATE511507T1 (es)
AU (1) AU2005213538A1 (es)
BR (1) BRPI0507435A (es)
CA (1) CA2555800C (es)
CR (1) CR8545A (es)
EA (1) EA011159B1 (es)
EC (1) ECSP066751A (es)
GB (1) GB0402492D0 (es)
GE (1) GEP20084361B (es)
IL (1) IL177004A0 (es)
MA (1) MA28348A1 (es)
NL (1) NL1028193C2 (es)
NO (1) NO20063944L (es)
PA (1) PA8623101A1 (es)
PE (1) PE20050772A1 (es)
TW (1) TWI300066B (es)
UY (1) UY28737A1 (es)
WO (1) WO2005077935A1 (es)
ZA (1) ZA200606236B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1912968A1 (en) * 2005-08-04 2008-04-23 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
EP1940842B1 (en) * 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
CA2625877A1 (en) * 2005-10-18 2007-04-26 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
JP5243274B2 (ja) * 2006-02-23 2013-07-24 ファイザー・リミテッド ４型メラノコルチン受容体アゴニストのピペリジノイルピロリジン
KR101036981B1 (ko) 2006-02-23 2011-05-25 화이자 리미티드 멜라노코르틴 제４형 수용체 효능제 피페리디노일피롤리딘
CN101821235B (zh) 2007-08-07 2012-11-14 武田药品工业株式会社 作为雄激素受体调节剂的吡咯烷-2-酮衍生物
UA99555C2 (en) 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US9981960B2 (en) * 2014-05-29 2018-05-29 Mitsubishi Tanabe Pharma Corporation Pyrrolidine compound and application as melanocortin receptor agonist
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
ES2753227T3 (es) 2015-08-04 2020-04-07 Astellas Pharma Inc Derivado de piperazina
CN112694436B (zh) * 2020-12-30 2022-07-08 济南周行医药科技有限公司 一种槟榔碱的合成方法
CN114211258B (zh) * 2021-11-04 2023-09-26 江阴市大久金属科技有限公司 高精密无缝钢管制备工艺

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20032325A3 (cs) * 2001-02-28 2004-02-18 Erck & Co., Inc. Acylované piperidinové deriváty
CA2439149C (en) * 2001-02-28 2012-04-24 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists

Also Published As

Publication number Publication date
WO2005077935A1 (en) 2005-08-25
BRPI0507435A (pt) 2007-07-03
EP1716135A1 (en) 2006-11-02
ATE511507T1 (de) 2011-06-15
AP2006003699A0 (en) 2006-08-31
NL1028193C2 (nl) 2006-04-20
EP1716135B1 (en) 2011-06-01
KR100830763B1 (ko) 2008-05-19
CA2555800A1 (en) 2005-08-25
NO20063944L (no) 2006-10-31
JP2007534668A (ja) 2007-11-29
AU2005213538A1 (en) 2005-08-25
KR20060127125A (ko) 2006-12-11
CN1930146A (zh) 2007-03-14
MA28348A1 (fr) 2006-12-01
NL1028193A1 (nl) 2005-08-08
EA200601279A1 (ru) 2006-12-29
PE20050772A1 (es) 2005-10-31
TW200526625A (en) 2005-08-16
GEP20084361B (en) 2008-04-29
EA011159B1 (ru) 2009-02-27
IL177004A0 (en) 2006-12-10
UY28737A1 (es) 2005-09-30
GB0402492D0 (en) 2004-03-10
CR8545A (es) 2007-09-03
JP4031814B2 (ja) 2008-01-09
ECSP066751A (es) 2006-11-16
CA2555800C (en) 2010-06-15
ZA200606236B (en) 2008-04-30
TWI300066B (en) 2008-08-21
AR048232A1 (es) 2006-04-12

Similar Documents

Publication Publication Date Title
PA8623101A1 (es) Compuestos farmaceuticamente activos
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
CR10696A (es) Compuestos de n-metilaminometil isoindol, composiciones que las comprenden y metodos que utilizan los mismos
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
NI201000209A (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato
ECSP10010693A (es) Compuestos pirazólicos 436
UY31524A1 (es) Nuevos compuestos 010
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
UY31344A1 (es) Metansulfonamidas n-(3-ter-butil-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-2-metoxi-aril) sustituidas, solvatos, hidratos, formas cristalinas y sus sales farmacéuticamente aceptables,proceso de preparación,composiciones y aplicaciones.
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
UY30327A1 (es) Nuevos compuestos ii
UY30748A1 (es) Compuesto0s novedosos
ECSP10010722A (es) Compuestos orgánicos
UY33501A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
UY29267A1 (es) Derivados de piperidina y su uso como agentes antiinflamatorios
HN2012001162A (es) Triazolopiridinas
ECSP088666A (es) Derivados de las benzamidas y heteroarenos
UY29002A1 (es) Nuevos derivados de hidantoína, procesos parasu preparación, composiciones farmacéuticas que los contienen y su uso en terapia
UY30610A1 (es) Moduladores de mglur5
UY30976A1 (es) Nuevos derivados de quinolina, composiciones farmaccuticas que los contienen, procesos de preparacion y aplicaciones.
UY30808A1 (es) Derivados de benzotiazolonas, composiciones conteniéndolos y aplicaciones
UY29234A1 (es) Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones.
GT200600117A (es) Nuevos compuestos farmaceuticos
UY31456A1 (es) Derivados de 2-pirazinona como inhibidores de la elastasa de los neutrofilos